**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 11, 2013

# PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)

| Delaware | 94-3023969 |
| --- | --- |
| (State or Other Jurisdiction of Incorporation) | (I.R.S. Employer Identification No.) |

**932 Southwood Boulevard**
**Incline Village, Nevada 89451**
(Address of principal executive offices, with zip code)

**(775) 832-8500**
(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

*Press Release*

On March 11, 2013, PDL BioPharma, Inc. (the Company) issued a press release with revenue guidance for the first quarter ending March 31, 2013. A copy of the press release is attached hereto as Exhibit 99.1.

*Detailed Product Sales, Royalties and Manufacturing*

On March 11, 2013, the Company distributed to analysts covering the Company's securities and posted to its website a summary of certain information underlying the Company's receipt of royalty payments (the Information Sheet) to assist those analysts and its stockholders in valuing the Company's securities. The Information Sheet is based on information provided to the Company by its licensees and includes reported net sales revenues by licensed product, royalty revenue by licensed product and where certain licensed products are manufactured and sold. A copy of the Information Sheet is attached hereto as Exhibit 99.2

*Limitation of Incorporation by Reference*

In accordance with General Instruction B.2. of Current Report on Form 8-K, the information in Item 7.01 of this report, including Exhibits 99.1 and 99.2, is furnished and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information will not be deemed an admission as to the materiality of any such information that is required to be disclosed solely by Regulation FD

*Cautionary Statements*

This filing, the press release, the Information Sheet and the Company's statements herein and in the attached press release include and constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company's royalty assets or business and limit the Company's ability to pay dividends, purchase income generating assets and take other corporate actions are disclosed in the "Risk Factors" contained in the Company's 2012 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2013. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release |
| 99.2 | Information Sheet |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)

By: /s/ John P. McLaughlin
John P. McLaughlin
President, Chief Executive Officer and
Acting Chief Financial Officer

Dated: March 11, 2013

**EXHIBIT INDEX**

| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release |
| 99.2 | Information Sheet |

**Exhibit 99.1**

**Contacts:**
John McLaughlin
PDL BioPharma, Inc.
775-832-8500
John.McLaughlin@pdl.com

Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
Jennifer@cwcomm.org

**PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million**

INCLINE VILLAGE, NV, March 11, 2013 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase.

The forecasted growth in royalty revenues is driven by increased fourth quarter 2012 sales for all licensed products for which PDL receives royalties in the first quarter of 2013. Sales of Avastin®, Herceptin®, Lucentis®, Xolair® and Perjeta™ (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States (ex-US manufactured and sold). The net sales thresholds and the applicable royalty rates for the Genentech Products are outlined below:

| Genentech Products Made or Sold in US | Royalty Rate |
|---|---|
| Net sales up to $1.5 billion | 3.0% |
| Net sales between $1.5 billion and up to $2.5 billion | 2.5% |
| Net sales between $2.5 billion and up to $4.0 billion | 2.0% |
| Net sales exceeding $4.0 billion | 1.0% |
| | |
| Genentech Products Made and Sold ex-US | |
| Net sales | 3.0% |

The first quarter royalty payment received from Genentech included royalties based on worldwide sales.

Revenue guidance for the first quarter of 2013 is net of an estimated payment due under our February 2011 settlement agreement with Novartis AG (Novartis). PDL pays to Novartis certain amounts based on net sales of Lucentis, made by Novartis, during calendar year 2011 and beyond. The amount paid is less than we receive in royalties on such sales.

Reported worldwide sales for Avastin sales increased 10 percent in the fourth quarter of 2012 when compared to the same period in 2011. Ex-U.S. manufactured and sold Avastin sales represented 50 percent of total Avastin sales in the fourth quarter of 2012 as compared with 27 percent in the fourth quarter of 2011.

Reported worldwide sales for Herceptin increased 11 percent in the fourth quarter of 2012 when compared to the same period in 2011. Ex-U.S. manufactured and sold Herceptin sales represented 41 percent of total Herceptin sales in the fourth quarter of 2012 as compared with 35 percent in the fourth quarter of 2011.

Reported worldwide sales for Lucentis increased 12 percent in the fourth quarter of 2012 when compared to the same period in 2011. All sales of Lucentis were from inventory produced in the United States.

Reported worldwide sales for Tysabri increased 16 percent for the fourth quarter of 2012 compared to the same period in 2011. Tysabri royalties are determined at a flat rate as a percentage of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

**About PDL BioPharma**
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.



**Forward-looking Statements**
This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

- The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
- The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;
- The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
- The productivity of acquired income generating assets may not fulfill our revenue forecasts and, if secured by collateral, we may be undersecured and unable to recuperate our capital expenditures in the transaction;
- Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
- The outcome of pending litigation or disputes, including PDL's current dispute with Genentech related to ex-U.S. sales of Genentech licensed products;
- The change in foreign currency exchange rate;
- Positive or negative results in PDL's attempt to acquire income generating assets; and
- The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual report filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

**Royalty Revenue by Product ($ in 000's) ***

| Avastin | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 33,234 | - | - | - | 33,234 |
| 2012 | 23,215 | 41,670 | 25,955 | 30,041 | 120,882 |
| 2011 | 22,283 | 41,967 | 23,870 | 22,886 | 111,006 |
| 2010 | 16,870 | 44,765 | 29,989 | 24,922 | 116,547 |
| 2009 | 13,605 | 35,161 | 21,060 | 15,141 | 84,966 |
| 2008 | 9,957 | 30,480 | 19,574 | 12,394 | 72,405 |
| 2007 | 8,990 | 21,842 | 17,478 | 9,549 | 57,859 |
| 2006 | 10,438 | 15,572 | 15,405 | 12,536 | 53,952 |

| Herceptin | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 30,287 | - | - | - | 30,287 |
| 2012 | 25,702 | 44,628 | 30,433 | 28,307 | 129,070 |
| 2011 | 25,089 | 42,209 | 31,933 | 21,812 | 121,042 |
| 2010 | 23,402 | 38,555 | 27,952 | 25,441 | 115,350 |
| 2009 | 16,003 | 32,331 | 26,830 | 18,615 | 93,779 |
| 2008 | 14,092 | 34,383 | 28,122 | 20,282 | 96,880 |
| 2007 | 19,035 | 28,188 | 22,582 | 14,802 | 84,608 |
| 2006 | 15,142 | 19,716 | 21,557 | 20,354 | 76,769 |

| Lucentis | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 12,032 | - | - | - | 12,032 |
| 2012 | 10,791 | 27,938 | 12,552 | 11,097 | 62,377 |
| 2011 | 8,878 | 24,313 | 12,157 | 10,750 | 56,099 |
| 2010 | 7,220 | 19,091 | 10,841 | 8,047 | 45,198 |
| 2009 | 4,621 | 12,863 | 8,123 | 6,152 | 31,759 |
| 2008 | 3,636 | 11,060 | 7,631 | 4,549 | 26,876 |
| 2007 | 2,931 | 6,543 | 6,579 | 3,517 | 19,570 |
| 2006 | - | - | 289 | 3,335 | 3,624 |

| Xolair | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 5,930 | - | - | - | 5,930 |
| 2012 | 5,447 | 8,609 | 6,504 | 6,145 | 26,705 |
| 2011 | 4,590 | 7,621 | 5,916 | 5,823 | 23,949 |
| 2010 | 3,723 | 6,386 | 4,980 | 4,652 | 19,741 |
| 2009 | 2,665 | 5,082 | 4,085 | 3,722 | 15,553 |
| 2008 | 1,488 | 4,866 | 3,569 | 2,927 | 12,850 |
| 2007 | 1,684 | 3,942 | 3,332 | 2,184 | 11,142 |
| 2006 | 2,263 | 2,969 | 3,041 | 2,495 | 10,768 |

| Perjeta | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 340 | - | - | - | 340 |
| 2012 | - | - | 58 | 250 | 308 |
| 2011 | - | - | - | - | - |
| 2010 | - | - | - | - | - |
| 2009 | - | - | - | - | - |
| 2008 | - | - | - | - | - |
| 2007 | - | - | - | - | - |
| 2006 | - | - | - | - | - |

| Tysabri | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 12,965 | - | - | - | 12,965 |
| 2012 | 11,233 | 12,202 | 11,749 | 12,255 | 47,439 |

| | | | | | |
|---|---|---|---|---|---|
| 2011 | 9,891 | 10,796 | 11,588 | 11,450 | 43,725 |
| 2010 | 8,791 | 8,788 | 8,735 | 9,440 | 35,754 |
| 2009 | 6,656 | 7,050 | 7,642 | 8,564 | 29,912 |
| 2008 | 3,883 | 5,042 | 5,949 | 6,992 | 21,866 |
| 2007 | 839 | 1,611 | 2,084 | 2,836 | 7,370 |
| 2006 | - | - | - | 237 | 237 |

| Actemra | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 2,631 | - | - | - | 2,631 |
| 2012 | 1,705 | 2,074 | 2,145 | 2,462 | 8,385 |
| 2011 | 913 | 1,136 | 1,401 | 1,460 | 4,910 |
| 2010 | 1,587 | 237 | 315 | 688 | 2,827 |
| 2009 | 585 | 537 | 909 | 1,197 | 3,228 |
| 2008 | 44 | - | 146 | 369 | 559 |
| 2007 | 32 | - | - | 17 | 49 |
| 2006 | - | - | - | - | - |

*** As reported to PDL by its licensees**
**Totals may not sum due to rounding**

**Reported Net Sales Revenue by Product ($ in 000's) ***

| Avastin | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 1,653,108 | - | - | - | 1,653,108 |
| 2012 | 1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | 6,290,788 |
| 2011 | 1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | 6,231,255 |
| 2010 | 1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 6,344,605 |
| 2009 | 1,345,487 | 1,295,536 | 1,439,730 | 1,514,053 | 5,594,806 |
| 2008 | 980,715 | 1,084,930 | 1,180,427 | 1,239,382 | 4,485,454 |
| 2007 | 678,068 | 746,587 | 797,013 | 875,084 | 3,096,752 |
| 2006 | 439,318 | 516,052 | 570,551 | 592,897 | 2,118,817 |

| Herceptin | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 1,681,574 | - | - | - | 1,681,574 |
| 2012 | 1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | 6,454,759 |
| 2011 | 1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | 6,027,211 |
| 2010 | 1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 5,330,602 |
| 2009 | 1,210,268 | 1,133,993 | 1,226,435 | 1,278,626 | 4,849,323 |
| 2008 | 1,105,426 | 1,195,215 | 1,211,982 | 1,186,806 | 4,699,428 |
| 2007 | 891,761 | 949,556 | 979,602 | 1,015,033 | 3,835,952 |
| 2006 | 529,585 | 659,719 | 761,099 | 803,576 | 2,753,979 |

| Lucentis | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 1,203,179 | - | - | - | 1,203,179 |
| 2012 | 1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | 4,372,871 |
| 2011 | 887,757 | 943,418 | 1,052,809 | 1,075,015 | 3,958,999 |
| 2010 | 721,967 | 698,890 | 745,376 | 804,684 | 2,970,917 |
| 2009 | 462,103 | 469,736 | 555,296 | 615,212 | 2,102,347 |
| 2008 | 363,615 | 393,682 | 460,167 | 454,922 | 1,672,386 |
| 2007 | 224,820 | 219,579 | 299,995 | 322,300 | 1,066,695 |
| 2006 | - | - | 10,689 | 157,742 | 168,431 |

| Xolair | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 341,309 | - | - | - | 341,309 |
| 2012 | 310,234 | 314,638 | 347,796 | 340,431 | 1,313,100 |
| 2011 | 267,754 | 277,642 | 310,874 | 314,911 | 1,171,182 |
| 2010 | 228,859 | 225,878 | 251,055 | 263,389 | 969,179 |
| 2009 | 184,669 | 181,086 | 211,006 | 219,693 | 796,454 |
| 2008 | 137,875 | 169,521 | 177,179 | 183,753 | 668,329 |
| 2007 | 129,172 | 130,700 | 144,250 | 147,754 | 551,876 |
| 2006 | 95,241 | 99,354 | 112,608 | 118,002 | 425,204 |

| Perjeta | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 34,008 | - | - | - | 34,008 |
| 2012 | - | - | 5,080 | 25,000 | 30,079 |
| 2011 | - | - | - | - | - |
| 2010 | - | - | - | - | - |
| 2009 | - | - | - | - | - |
| 2008 | - | - | - | - | - |
| 2007 | - | - | - | - | - |
| 2006 | - | - | - | - | - |

| Tysabri | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 434,677 | - | - | - | 434,677 |

| | | | | | |
|---|---|---|---|---|---|
| 2012 | 374,430 | 401,743 | 391,623 | 408,711 | 1,576,508 |
| 2011 | 329,696 | 356,876 | 388,758 | 381,618 | 1,456,948 |
| 2010 | 293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 |
| 2009 | 221,854 | 229,993 | 257,240 | 285,481 | 994,569 |
| 2008 | 129,430 | 163,076 | 200,783 | 233,070 | 726,359 |
| 2007 | 30,468 | 48,715 | 71,972 | 94,521 | 245,675 |
| 2006 | - | - | - | 7,890 | 7,890 |

| Actemra | Q1 | Q2 | Q3 | Q4 | Total |
|---|---|---|---|---|---|
| 2013 | 87,703 | - | - | - | 87,703 |
| 2012 | 56,662 | 66,624 | 71,505 | 82,053 | 276,843 |
| 2011 | 30,433 | 35,370 | 46,709 | 48,671 | 161,183 |
| 2010 | 52,908 | 5,405 | 10,493 | 22,919 | 91,725 |
| 2009 | 19,504 | 17,920 | 30,313 | 39,888 | 107,625 |
| 2008 | 1,452 | 1,377 | 5,981 | 12,305 | 21,115 |
| 2007 | - | - | - | 1,137 | 1,137 |
| 2006 | - | - | - | - | - |

*** As reported to PDL by its licensees**

**Totals may not sum due to rounding**

**Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) ***

| Avastin Sales | 2011 - Q4 | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold | 684,878 | 652,824 | 724,483 | 679,914 | 710,501 | 664,109 |
| US Made & ex-US Sold | 375,830 | 448,037 | 532,979 | 428,976 | 281,905 | 161,369 |
| ex-US Made & Sold | 409,286 | 401,896 | 316,265 | 442,437 | 670,572 | 827,629 |
| Total | 1,469,994 | 1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | 1,653,108 |
| US Made & Sold | 47% | 43% | 46% | 44% | 43% | 40% |
| US Made & ex-US Sold | 26% | 30% | 34% | 28% | 17% | 10% |
| ex-US Made & Sold | 28% | 27% | 20% | 29% | 40% | 50% |

| Herceptin Sales | 2011 - Q4 | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold | 453,168 | 456,920 | 497,109 | 503,612 | 515,790 | 514,113 |
| US Made & ex-US Sold | 612,908 | 523,353 | 466,477 | 545,625 | 552,127 | 486,400 |
| ex-US Made & Sold | 366,695 | 534,982 | 661,727 | 614,459 | 582,578 | 681,060 |
| Total | 1,432,771 | 1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | 1,681,574 |
| US Made & Sold | 32% | 30% | 31% | 30% | 31% | 31% |
| US Made & ex-US Sold | 43% | 35% | 29% | 33% | 33% | 29% |
| ex-US Made & Sold | 26% | 35% | 41% | 37% | 35% | 41% |

| Lucentis Sales | 2011 - Q4 | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold | 428,884 | 433,428 | 412,131 | 385,746 | 381,592 | 392,207 |
| US Made & ex-US Sold | 646,131 | 645,665 | 674,411 | 711,795 | 728,103 | 810,972 |
| ex-US Made & Sold | - | - | - | - | - | - |
| Total | 1,075,015 | 1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | 1,203,179 |
| US Made & Sold | 40% | 40% | 38% | 35% | 34% | 33% |
| US Made & ex-US Sold | 60% | 60% | 62% | 65% | 66% | 67% |
| ex-US Made & Sold | 0% | 0% | 0% | 0% | 0% | 0% |

| Xolair Sales | 2011 - Q4 | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold | 188,728 | 185,505 | 193,600 | 211,702 | 210,892 | 207,976 |
| US Made & ex-US Sold | - | - | - | - | - | - |
| ex-US Made & Sold | 126,184 | 124,729 | 121,039 | 136,094 | 129,540 | 133,333 |
| Total | 314,911 | 310,234 | 314,638 | 347,796 | 340,431 | 341,309 |
| US Made & Sold | 60% | 60% | 62% | 61% | 62% | 61% |
| US Made & ex-US Sold | 0% | 0% | 0% | 0% | 0% | 0% |
| ex-US Made & Sold | 40% | 40% | 38% | 39% | 38% | 39% |

| Perjeta Sales | 2011 - Q4 | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold | - | - | - | 5,080 | 24,571 | 32,377 |
| US Made & ex-US Sold | - | - | - | - | 428 | 1,632 |
| ex-US Made & Sold | - | - | - | - | - | - |
| Total | - | - | - | 5,080 | 25,000 | 34,008 |
| US Made & Sold | 0% | 0% | 0% | 100% | 98% | 95% |
| US Made & ex-US Sold | 0% | 0% | 0% | 0% | 2% | 5% |
| ex-US Made & Sold | 0% | 0% | 0% | 0% | 0% | 0% |

| Total Sales | 2011 - Q4 | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold | 1,755,657 | 1,728,678 | 1,827,323 | 1,786,053 | 1,843,345 | 1,810,783 |
| US Made & ex-US Sold | 1,634,869 | 1,617,054 | 1,673,867 | 1,686,395 | 1,562,564 | 1,460,373 |
| ex-US Made & Sold | 902,165 | 1,061,607 | 1,099,031 | 1,192,990 | 1,382,690 | 1,642,023 |
| Total | 4,292,691 | 4,407,339 | 4,600,221 | 4,665,438 | 4,788,598 | 4,913,178 |
| US Made & Sold | 41% | 39% | 40% | 38% | 38% | 37% |
| US Made & ex-US Sold | 38% | 37% | 36% | 36% | 33% | 30% |
| | | | | | | |

| | | | | | | |
|---|---|---|---|---|---|---|
| ex-US Made & Sold | 21% | 24% | 24% | 26% | 29% | 33% |

*** As reported to PDL by its licensees**
**Totals may not sum due to rounding**